2
Clinical Trials associated with Tenofovir Alafenamide Fumarate/ElvitegravirA Double-Blind, Placebo-Controlled, Randomized Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Rectally Administered Tenofovir Alafenamide/Elvitegravir Inserts
This is a double-blind, placebo-controlled, randomized two-phase study to evaluate the safety and pharmacokinetics (PK) of two TAF/EVG inserts administered rectally for 3 consecutive days, then every other day for 14 days.
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels
The purpose of this study is to evaluate the safety and pharmacokinetics of rectal administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels in HIV-uninfected individuals.
100 Clinical Results associated with Tenofovir Alafenamide Fumarate/Elvitegravir
100 Translational Medicine associated with Tenofovir Alafenamide Fumarate/Elvitegravir
100 Patents (Medical) associated with Tenofovir Alafenamide Fumarate/Elvitegravir
100 Deals associated with Tenofovir Alafenamide Fumarate/Elvitegravir